What is the Formulary Tool and how does it work?

The Formulary Tool offers formulary coverage data for most ZIP codes. Once a ZIP code is entered, you will see the percentage of insured lives covered in your area, commercial healthcare plans that cover DEXILANT, and Medicare Part D and Medicaid data. Plus, you can compare DEXILANT coverage.

Can my patients use the Formulary Tool?

This tool is intended for HCPs, pharmacists, and office staff.

On my mobile device, what is the URL to load the Formulary Tool?

www.dexilanthcp.com/cost-coverage/formulary/

What number do I call for general questions about the DEXILANT Instant Savings Card?

Please call 1-866-279-5598.

I am a pharmacist and am having difficulties processing the Instant Savings Card. What should I do?

Please call 1-866-279-5598.

The patient has an Instant Savings Card, but gets his or her prescription via mail order. Can the patient still get the discount?

Yes. Please advise patients that they should visit www.patientrebateonline.com and follow the instructions. If they need further information, direct them to call 1-866-279-5598.

Is the DEXILANT Instant Savings Card a one-time-use card?

No. DEXILANT Instant Savings Cards can be used for multiple prescriptions and refills. If you have any questions, please call us at 1-866-279-5598.

What are patients’ eligibility requirements to use the DEXILANT Instant Savings Card?

The DEXILANT Instant Savings Card cannot be used if the patient is a beneficiary of, or any part of the patient's prescription is covered by: (1) any federal or state healthcare program (Medicare, Medicaid, TriCARE, etc.), including a state pharmaceutical assistance program, (2) the Medicare Prescription Drug Program (Part D), or if the patient is currently in the coverage gap, or (3) insurance that is paying the entire cost of the prescription.

What are the pharmacist’s requirements in submitting the DEXILANT Instant Savings Card for reimbursement?

By submitting this offer for reimbursement to McKesson, you certify that: (1) you have dispensed DEXILANT to an eligible patient in accordance with the Eligibility Requirements of this offer and the accompanying prescription; (2) you have not submitted and will not submit a claim for reimbursement for the portion of the drug covered by this coupon to any payor; (3) your participation in this program is consistent with all applicable laws and any obligations, contractual or otherwise, that you may have as a pharmacy provider; and (4) submission of claims are subject to the LoyaltyScript® program Terms and Conditions posted at www.mckesson.com/mprstnc. For questions about processing, please call 1-866-279-5598.

Where can I find more detailed information about DEXILANT?

You can find more information about DEXILANT by selecting any of the following sections:

How can I request to see a Sales Representative?

DEXILANT Select is a program designed to give you access to valuable resources and tools, including the option to request a visit from a Sales Representative. If one is not available in your area, you can sign up to receive information and materials directly from DEXILANT. Join DEXILANT Select now to get started!

How can I request DEXILANT samples?

DEXILANT Select is a program developed to give you access to valuable resources and tools, including the option to request DEXILANT samples online. Becoming a part of DEXILANT Select is easy—join now!

Frequently asked questions about the DEXILANT Select program

Why do I have to register?

The member section of this site is intended for licensed U.S. healthcare professionals only, and registration enables us to ensure that the videos and resources are being viewed by the community they are intended to serve. Visit our privacy policy for more details regarding disclosure of personal identifying information.

Why am I unable to receive samples?

Only healthcare professionals who are able to write prescriptions may receive DEXILANT samples. For this reason, we need to verify your status through your state license number, which you provide when you register for DEXILANT Select. If you are a prescriber and a member of DEXILANT Select, and you are still unable to receive samples or you need more help, please call 1-888-874-2798 for support from our sample fulfillment center.

My email address has changed or will be changing. How do I update my profile?

A current personal email address (i.e., not shared with another person) is critical for access to DEXILANT Select member-only content. You may easily update your email address and other profile information by visiting My account when you are signed in. Visit our privacy policy for more details regarding disclosure of personal identifying information.

I am having trouble signing in to DEXILANT Select. Where can I find help?

If you have forgotten your password, complete and submit the forgot-password form and we will email it to you. If you need additional help, please visit DEXILANT Select member support.

I have registered for DEXILANT Select. When will I receive invitations to physician-led programs?

Our goal is to communicate with you only when we have something valuable to offer. We have a library of valuable content and our resources are continuously updated. Generally, you can expect to receive program invitations from us periodically.

How do I sign up for interactive teleconferences?

When you have registered for DEXILANT Select, you will receive email invitations to teleconferences held during convenient hours. These email invitations will give you the details you need to dial in and listen to physicians explain gastroesophageal reflux disease and DEXILANT.

The information in the DEA field of my account information is incorrect. How can I update it?

Once signed in, you can update your account at any time by visiting My account at the top of any page. Select “Request change to DEA number” and fill out and submit the support request. Your DEA number will be updated after verification.

  1. DEXILANT (dexlansoprazole) prescribing information. Takeda Pharmaceuticals.
  2. Metz DC, Howden CW, Perez MC, et al. Aliment Pharmacol Ther. 2009;29:742‐754.
  3. Data on file. Takeda Pharmaceuticals.
  4. Vakily M, Zhang W, Wu J, et al. Curr Med Res Opin. 2009;25:627-638.

Important Safety Information

  • DEXILANT is contraindicated in patients with known hypersensitivity to any component of the formulation. Hypersensitivity reactions, including anaphylaxis, have been reported. Acute interstitial nephritis has been reported with other proton pump inhibitors (PPIs), including lansoprazole. Discontinue DEXILANT if acute interstitial nephritis develops.
  • PPIs, including DEXILANT, are contraindicated with rilpivirine‑containing products.
  • In adults, symptomatic response with DEXILANT does not preclude the presence of gastric malignancy. Consider additional follow‑up and diagnostic testing.
  • PPI therapy may be associated with increased risk of Clostridium difficile associated diarrhea.
  • Long‑term (≥ 1 year) and multiple daily dose PPI therapy may be associated with an increased risk for osteoporosis‑related fractures of the hip, wrist, or spine. Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the conditions being treated.
  • New onset or worsening of cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE) have been reported in patients taking PPIs. The majority of PPI‑induced lupus erythematosus cases were CLE. Avoid administration of PPIs for longer than medically indicated. Discontinue DEXILANT and refer the patient to an appropriate specialist for evaluation, if signs or symptoms of CLE or SLE occur. Most patients improve with discontinuation of the PPI alone in 4 to 12 weeks.
  • Daily treatment with any acid‑suppressing medications over a long period of time (e.g., > 3 years) may lead to malabsorption or a deficiency of cyanocobalamin (Vitamin B‑12).
  • Hypomagnesemia has been reported rarely with prolonged treatment with PPIs.
  • Serum chromogranin A (CgA) levels increase secondary to drug‑induced decreases in gastric acidity which may cause false positive results in diagnostic investigations for neuroendocrine tumors. Temporarily stop DEXILANT treatment ≥ 14 days before assessing CgA levels and consider repeating the test if initial CgA levels are high.
  • Concomitant use of PPIs with methotrexate may elevate and prolong serum concentrations of methotrexate and/or its metabolite, possibly leading to toxicity. With high dose methotrexate administration, consider a temporary withdrawal of DEXILANT.
  • Most commonly reported adverse reactions in adults were diarrhea (4.8%), abdominal pain (4.0%), nausea (2.9%), upper respiratory tract infection (1.9%), vomiting (1.6%), and flatulence (1.6%).
  • The adverse reaction profile in patients age 12 to 17 years was similar to adults. The most commonly reported adverse reactions in patients age 12 to 17 years (≥ 5%) were headache, abdominal pain, diarrhea, nasopharyngitis, and oropharyngeal pain.
  • Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir, and nelfinavir) when used concomitantly with DEXILANT may reduce antiviral effect. Avoid concomitant use of nelfinavir with DEXILANT. Increased exposure of other antiretroviral drugs (e.g., saquinavir) when used concomitantly with DEXILANT may increase toxicity of the antiretroviral drugs.
  • Patients taking concomitant warfarin may require monitoring for increases in international normalized ratio (INR) and prothrombin time (PT). Increases in INR and PT time may lead to abnormal bleeding and even death.
  • DEXILANT may interfere with absorption of drugs for which gastric pH is important for bioavailability (e.g., digoxin, iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil [MMF], ketoconazole/itraconazole). Use DEXILANT with caution in transplant patients receiving MMF.
  • Concomitant tacrolimus use may increase tacrolimus whole blood concentrations.
  • A hyper‑response in gastrin secretion in response to the secretin stimulation test may falsely suggest gastrinoma. Temporarily stop DEXILANT treatment ≥ 30 days before assessing to allow gastrin levels to return to baseline.
  • Avoid concomitant use of DEXILANT with St. John’s Wort or rifampin due to decreased exposure of DEXILANT.
  • No studies have been conducted in patients with severe hepatic impairment (Child‑Pugh Class C). The use of DEXILANT is not recommended for these patients.

Indications

DEXILANT (dexlansoprazole) 30 mg and 60 mg delayed‑release capsules are indicated in patients ≥ age 12 years for:

  • Healing all grades of erosive esophagitis (EE) for up to 8 weeks
  • Maintaining healing of EE and relief of heartburn for up to 6 months in adults and up to 16 weeks in patients age 12 to 17 years
  • Treating heartburn associated with symptomatic non‑erosive gastroesophageal reflux disease (GERD) for 4 weeks

Use of DEXILANT in patients age 12 to 17 years is supported by evidence from adequate and well‑controlled studies of DEXILANT capsules in adults with additional safety, efficacy and pharmacokinetic data in patients age 12 to 17 years.

The safety and effectiveness of DEXILANT have not been established in patients < 12 years of age.


Please see full Prescribing Information, including Medication Guide for DEXILANT.

Important Safety Information

Important Safety Information

  • DEXILANT is contraindicated in patients with known hypersensitivity to any component of the formulation. Hypersensitivity reactions, including anaphylaxis, have been reported. Acute interstitial nephritis has been reported with other proton pump inhibitors (PPIs), including lansoprazole. Discontinue DEXILANT if acute interstitial nephritis develops.
  • PPIs, including DEXILANT, are contraindicated with rilpivirine‑containing products.
  • In adults, symptomatic response with DEXILANT does not preclude the presence of gastric malignancy. Consider additional follow‑up and diagnostic testing.
  • PPI therapy may be associated with increased risk of Clostridium difficile associated diarrhea.
  • Long‑term (≥ 1 year) and multiple daily dose PPI therapy may be associated with an increased risk for osteoporosis‑related fractures of the hip, wrist, or spine. Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the conditions being treated.
  • New onset or worsening of cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE) have been reported in patients taking PPIs. The majority of PPI‑induced lupus erythematosus cases were CLE. Avoid administration of PPIs for longer than medically indicated. Discontinue DEXILANT and refer the patient to an appropriate specialist for evaluation, if signs or symptoms of CLE or SLE occur. Most patients improve with discontinuation of the PPI alone in 4 to 12 weeks.
  • Daily treatment with any acid‑suppressing medications over a long period of time (e.g., > 3 years) may lead to malabsorption or a deficiency of cyanocobalamin (Vitamin B‑12).
  • Hypomagnesemia has been reported rarely with prolonged treatment with PPIs.
  • Serum chromogranin A (CgA) levels increase secondary to drug‑induced decreases in gastric acidity which may cause false positive results in diagnostic investigations for neuroendocrine tumors. Temporarily stop DEXILANT treatment ≥ 14 days before assessing CgA levels and consider repeating the test if initial CgA levels are high.
  • Concomitant use of PPIs with methotrexate may elevate and prolong serum concentrations of methotrexate and/or its metabolite, possibly leading to toxicity. With high dose methotrexate administration, consider a temporary withdrawal of DEXILANT.
  • Most commonly reported adverse reactions in adults were diarrhea (4.8%), abdominal pain (4.0%), nausea (2.9%), upper respiratory tract infection (1.9%), vomiting (1.6%), and flatulence (1.6%).
  • The adverse reaction profile in patients age 12 to 17 years was similar to adults. The most commonly reported adverse reactions in patients age 12 to 17 years (≥ 5%) were headache, abdominal pain, diarrhea, nasopharyngitis, and oropharyngeal pain.
  • Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir, and nelfinavir) when used concomitantly with DEXILANT may reduce antiviral effect. Avoid concomitant use of nelfinavir with DEXILANT. Increased exposure of other antiretroviral drugs (e.g., saquinavir) when used concomitantly with DEXILANT may increase toxicity of the antiretroviral drugs.
  • Patients taking concomitant warfarin may require monitoring for increases in international normalized ratio (INR) and prothrombin time (PT). Increases in INR and PT time may lead to abnormal bleeding and even death.
  • DEXILANT may interfere with absorption of drugs for which gastric pH is important for bioavailability (e.g., digoxin, iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil [MMF], ketoconazole/itraconazole). Use DEXILANT with caution in transplant patients receiving MMF.
  • Concomitant tacrolimus use may increase tacrolimus whole blood concentrations.
  • A hyper‑response in gastrin secretion in response to the secretin stimulation test may falsely suggest gastrinoma. Temporarily stop DEXILANT treatment ≥ 30 days before assessing to allow gastrin levels to return to baseline.
  • Avoid concomitant use of DEXILANT with St. John’s Wort or rifampin due to decreased exposure of DEXILANT.
  • No studies have been conducted in patients with severe hepatic impairment (Child‑Pugh Class C). The use of DEXILANT is not recommended for these patients.

Indications

DEXILANT (dexlansoprazole) 30 mg and 60 mg delayed‑release capsules are indicated in patients ≥ age 12 years for:

  • Healing all grades of erosive esophagitis (EE) for up to 8 weeks
  • Maintaining healing of EE and relief of heartburn for up to 6 months in adults and up to 16 weeks in patients age 12 to 17 years
  • Treating heartburn associated with symptomatic non‑erosive gastroesophageal reflux disease (GERD) for 4 weeks

Use of DEXILANT in patients age 12 to 17 years is supported by evidence from adequate and well‑controlled studies of DEXILANT capsules in adults with additional safety, efficacy and pharmacokinetic data in patients age 12 to 17 years.

The safety and effectiveness of DEXILANT have not been established in patients < 12 years of age.


Please see full Prescribing Information, including Medication Guide for DEXILANT.